Strengthening Innovation and Compliance Across Pharma, Medical China Regulatory and Cosmetics
China continues to advance its life sciences regulatory framework with a strong emphasis on balancing innovation and regulatory oversight. Recent updates issued by the National Medical Products Administration (NMPA) and the Center for Drug Evaluation (CDE) introduce new clinical evaluation guidance for pharmaceuticals and enhanced technical standards for cosmetic ingredients. These measures signal a continued shift toward life cycle-based regulation, scientific consistency, and higher quality standards across regulated products.
Strengthening Innovation and Compliance Across Pharma, Medical China Regulatory and Cosmetics
China’s National Medical Products Administration (NMPA) has introduced major regulatory updates across pharmaceuticals, medical devices, and cosmetics, emphasizing innovation, lifecycle supervision, and strengthened technical standards. These changes reflect China’s push toward a more predictable, science‑driven regulatory environment that supports development while reinforcing compliance.
ANVISA and the ICH: How Regulatory Harmonization Strengthens the Brazilian Pharmaceutical Sector
Brazil’s participation in the ICH (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use) marks a strategic milestone for the national pharmaceutical industry. This Blog explains what the ICH is, the importance of ANVISA’s presence in this global forum, and how regulatory harmonization drives innovation and access to new treatments in the country.
ANVISA explains how drug safety is assessed in the pharmacovigilance cycle
Pharmacovigilance is essential to ensure that medicines marketed in Brazil continue to be safe and effective over time. Even after approval and market entry, these products continue to be monitored through a structured cycle that involves detecting adverse events, analyzing risks and adopting corrective measures. In this blog, you will understand how this process coordinated by ANVISA works, what the roles of each agent involved are and why the participation of society is so important.
ANVISA Opens Public Consultation on New Regulatory Framework for Medical Devices in Brazil
Brazil’s national health surveillance agency, ANVISA, has launched a targeted public consultation as part of its effort to revise and modernize the regulatory framework for medical devices. This initiative aims to align Brazilian regulations with international best practices, enhance patient safety, and foster innovation. Stakeholders across the health and regulatory sectors are invited to submit their contributions and insights.
Mexico’s Patent Office, COFEPRIS Sign Agreement on Drug Patents
Officials with Mexico’s patent office and its pharmaceutical regulator have signed a new agreement aimed at preemptively clarifying patent protections for drugs in hopes of speeding the review process.